# Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA

> **NCT06509958** · PHASE2 · TERMINATED · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 15 (actual)

## Conditions studied

- Postoperative Pain Management in Total Knee Arthroplasty

## Interventions

- **DRUG:** HR18034
- **DRUG:** Ropivacaine Hydrochloride Injection

## Key facts

- **NCT ID:** NCT06509958
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-08-20
- **Primary completion:** 2024-10-10
- **Final completion:** 2024-10-10
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Sponsor's R\&D Strategy adjusted
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06509958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06509958, "Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06509958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*